Introduction
============

Neoadjuvant chemoradiotherapy, followed by total mesorectal excision (TME), is the current standard treatment for locally advanced rectal adenocarcinoma.[@b1-cmar-11-1579] Compared with postoperative chemoradiotherapy, neoadjuvant chemoradiotherapy reduced the local relapse rate and decreased acute and long-term toxicities.[@b2-cmar-11-1579],[@b3-cmar-11-1579]

After neoadjuvant chemoradiotherapy with conventional dosage (45--50 Gy), 13.9%--19.2% of patients with locally advanced rectal cancer had a pathological complete response (pCR),[@b4-cmar-11-1579]--[@b8-cmar-11-1579] and pCR was reported to be associated with better local control (LC) and survival.[@b4-cmar-11-1579],[@b9-cmar-11-1579] In the CAO/ARO/AIO-94 trial, the 10-year cumulative incidence of distant metastasis rates were 10.5% and 39.6% for patients with pCR and poor response (*P*=0.005), respectively, following neoadjuvant chemoradiotherapy. The corresponding disease-free survival (DFS) rates were 89.5% and 63% (*P*=0.008), respectively.[@b9-cmar-11-1579] Park et al reported that the 5-year overall survival (OS) rates were 93.4% and 77.3% for the patients in pCR and poor response groups (*P*=0.002), respectively, and the 5-year recurrence-free survival rates were 90.5% and 58.5% (*P*\<0.001), respectively.[@b4-cmar-11-1579] In addition, pCR or good response will also increase the number of patients eligible for organ-preserving treatment and improve the quality of life of patients.

In attempts to improve the pCR and survival, several large, randomized, Phase III trials addressed the addition of oxaliplatin to 5-Fu or capecitabine.[@b5-cmar-11-1579]--[@b8-cmar-11-1579],[@b10-cmar-11-1579]--[@b12-cmar-11-1579] However, most studies (ACCORD 12, STAR-01, R-04) demonstrated that the combined chemotherapy regimen could not improve the pCR and survival rates and were associated with higher toxicities.[@b6-cmar-11-1579],[@b7-cmar-11-1579],[@b10-cmar-11-1579],[@b11-cmar-11-1579] Based on these results, the addition of oxaliplatin to neoadjuvant chemotherapy is not recommended at present.

The tumor response was associated with the dose delivered.[@b13-cmar-11-1579] An alternative strategy to improve the pCR and survival was dose-escalated radiotherapy. Combined with an accelerator with a high modulation capability and a megavolt computed tomography (MVCT), Tomotherapy fully integrates intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy. For rectal cancer patients, Tomotherapy allows more accurate and precise boost irradiation delivered to the primary tumor than IMRT and three-dimensional conformal radiation therapy (3D-CRT) did, which were used in most previous studies.[@b14-cmar-11-1579] In this study, we reported the efficacy and toxicity of dose-escalated Tomotherapy combined with chemotherapy in mid--low, locally advanced rectal carcinoma patients.

Patients and methods
====================

Patients
--------

We conducted this study from May 2012 to October 2017. The eligibility criteria were as follows: histologically confirmed rectal carcinoma; local advanced stage (cT3-4N0-2M0 or cT1-4N1-2M0); mid--low rectal cancer (≤10 cm from anal verge). Patients received surgery after concurrent chemo-radiotherapy. Pretreatment evaluation included complete history and physical examination, digital rectal examination (DRE), blood count, renal and liver function, colonoscopy, biopsy, chest and abdomen computed tomography (CT), pelvic magnetic resonance imaging (MRI), and transrectal ultrasound. Some patients received positron emission tomography/computed tomography (PET/CT).

Radiotherapy
------------

All patients received a CT simulation (16-slice Philips Brilliance CT BigBore, Deventer, Netherlands) in the supine position with oral and intravenous contrast agents. Bladder and rectum preparation were conducted before the CT scan. The gross tumor volume (GTV) and clinical target volume (CTV) were contoured on the axial CT slices. The GTV included the primary tumor (GTV-T) and involved lymph nodes (GTV-N). The GTV-T scans were delineated based on the pelvic MRI and taking the DRE, endoscopy, and pelvic ultrasound into consideration. Involved lymph nodes were defined as short diameter \>1 cm or confirmed by diffusion-weighted imaging or PET/CT. CTV covered GTV-T, GTV-N (if any), the complete mesorectum, and pelvic lymph node region (including presacral, internal iliac, obturator), with an upper margin at the L5--S1 interspace. The planning clinical target volume (PCTV) was the CTV plus 8 mm margin craniocaudal direction, and 6 mm in anteroposterior and left--right directions. The planning gross tumor volume (PGTV) was created by adding a 5 mm margin to the GTV-T and GTV-N.

A dose of 45/50 Gy in 25 fractions was prescribed to the PCTV. PGTV (including PGTV-T and PGTV-N) was boosted to 55 Gy with a simultaneously integrated boost. Radiotherapy plans were generated on the Tomotherapy treatment planning system (Tomotherapy Inc., Madison, WI, USA). The Tomotherapy planning parameters were a 2.5-cm field width, a pitch of 0.25, and a maximum modulation factor of 2.5. The planning goals were delivering at least 95% of the prescribed dose to 95% of the PCTV or PGTV. MVCT was used for image guidance before each treatment delivery. Patients were repositioned after co-registration of MVCT images with the planning kilovolt CT images.

Chemotherapy
------------

All patients received concurrent chemoradiotherapy. The concurrent chemotherapy regimen included oral capecitabine (825 mg/m^2^ twice per day, 5 days per week) with or without oxaliplatin at a dose of 50 mg/m^2^ once per week for 6 weeks. Different chemotherapy regimens were given according to the patient's condition. Postoperative chemotherapy was individualized.

Surgery
-------

Before surgery, patients received a pelvic MRI/transrectal ultrasound for reassessment of staging and resectability by surgeons. TME surgery was performed for rectal cancer patients at least 6 weeks after neoadjuvant radiotherapy. Whether to perform sphincter-preserving surgery or not was decided by the attending surgeon, based on the distance of the tumor to the anal sphincter, the clinical response to neo-adjuvant treatment, and the patient's preference. Prophylactic ileostomy was performed for patients with low rectal cancer receiving sphincter-preserving TME. Transanal endoscopic microsurgery (TEM) was conducted for some patients with very low rectal cancer (\<3 cm from the anal verge), acquired clinical complete response (cCR) after neoadjuvant treatment, and a strong desire to preserve the sphincter.

Follow-up and evaluation of toxicities
--------------------------------------

Patients had follow-up examinations every 3 months during the first 2 years, every 6 months during the next 3--5 years, and then once each year. Carbohydrate antigen 19--9 and carcinoembryonic antigen levels were measured every 3 months together with a rectal examination that included an MRI of the pelvis and CT scan of the thorax and abdomen. Chemoradio-therapy-related toxicities and postoperative complications were recorded. Acute toxicities during chemoradiotherapy were evaluated every week. Toxicities were evaluated with Common Terminology Criteria for Adverse Events, version 3.0.

Statistics
----------

The primary end point of this study was the pCR rate. The secondary end points, including resection rate, sphincter-preserving rate, downstaging rate, acute and postoperative complications, pattern of failure, and survival, were also calculated. OS, DFS, and LC rates were estimated with the Kaplan--Meier methods, and the univariate log rank test was used to evaluate the significance of prognostic factors for survival. Multivariate analysis, using the Cox proportional regression method, was performed for the covariates selected in the univariate analysis. An equivalent dose in 2-Gy fractions (EQD2) was calculated with α/β=10 for the tumor. A significance level of 0.05 was used. All the statistical analyses were performed using SPSS 22.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

Patients
--------

A total of 141 patients were enrolled. Patients' and tumors' characteristics are detailed in [Table 1](#t1-cmar-11-1579){ref-type="table"}. All patients were diagnosed with locally advanced rectal cancer, 129 patients (91.5%) with stage cT3 or cT4; 121 patients (85.8%) had positive lymph nodes. The location of tumors was in the lower rectum in 88 patients (62.4%; [Table 1](#t1-cmar-11-1579){ref-type="table"}).

Treatment and acute toxicities
------------------------------

A dose of 50 Gy in 25 fractions was delivered to the pelvic of 55 patients (39.0%), and 45 Gy was prescribed for 86 patients (61.0%). All patients completed radiotherapy. The median duration of radiotherapy was 35 days (range, 34--50 days). One patient prolonged the radiotherapy time due to grade III leukopenia, but the total dose remained unchanged. Capecitabine alone was used in 56.7% (80/141) of patients and XELOX in 43.3% (61/141) of patients. Adjuvant chemotherapy was conducted in 70.2% (99/141) patients, including capecitabine in 36 patients and XELOX in 63 patients. Grades 3--4 leukopenia, anemia, and thrombocytopenia were observed in 8 (5.7%) patients, 2 (1.4%) patients, and 4 (2.8%) patients, respectively. Eleven patients (7.8%) developed grade 3 diarrhea.

Surgery and postoperative complications
---------------------------------------

Surgery was performed on all patients, including TEM in seven patients. Negative margins were observed in 138 patients (97.9%), and 113 patients (80.1%) underwent sphincter-preserving resection. TEM was conducted in seven patients: T3N1bM0 in four patients, T3N0M0 in two patients, and T3bN2M0 in one patient, and obtained cCR after chemoradiotherapy. Five of them had pathologic CR and the other two patients had pathologic T2 disease (with spotted and focal residual tumor in the muscle layer) after surgery.

Fifteen of 141 patients (10.6%) experienced postoperative complications, including 6 patients with bowel obstruction, 3 patients with rectovaginal fistula, 1 patient with urosche-sis, 2 patients with anastomotic fistula, 1 patient with anal fistula, 1 patient with rectovesical fistula, and 1 patient with anastomotic stenosis.

Pathologic response
-------------------

Downstaging was observed in 121 patients (85.8%), including 80 patients (56.7%) with T downstaging and 101 patients (83.5%) with N downstaging. A pCR was observed in 32 patients (22.7%). Compared with capecitabine alone, XELOX presented no significant difference in pCR (*P*=0.119). Pathologic T0 was also found in 32 patients (22.7%). Of the 121 patients with positive lymph nodes before treatment, negative lymph node involvement was observed in 90 patients (74.4%).

Pattern of failure and survival
-------------------------------

The median follow-up was 38.5 months (range, 9.3--73.6 months). Only 36 patients (25.5%) experienced treatment failure, including distant metastasis in 29 patients (20.6%) and pelvic recurrent in 7 patients (5.0%). The most common metastases were lung, followed by liver and bone. The estimated 5-year OS, DFS, and LC rates of patients were 75.1% (95% CI: 63.1%--83.7%), 70.9% (95% CI: 61.7%--78.3%), and 95.5% (95% CI: 90.2%--98.0%), respectively ([Figure 1A--C](#f1-cmar-11-1579){ref-type="fig"}). Univariate analysis showed that pCR (*P*=0.019) and sphincter preservation (*P*=0.027) were prognostic factors of DFS but did not improve OS and LC ([Table 2](#t2-cmar-11-1579){ref-type="table"}, [Figure 2](#f2-cmar-11-1579){ref-type="fig"}). Multivariate analysis demonstrated that pCR was independently significant for DFS (HR =0.13, 95% CI: 0.02--0.93, *P* = 0.043; [Table 3](#t3-cmar-11-1579){ref-type="table"}).

Discussion
==========

Compared with the addition of oxaliplatin,[@b6-cmar-11-1579],[@b7-cmar-11-1579],[@b10-cmar-11-1579],[@b11-cmar-11-1579] the ability to achieve a pCR appears promising with the use of primary tumor dose escalation for locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery. In a trial from China, 63 patients with locally advanced mid--low rectal cancer underwent radio therapy at two dose levels (41.8 Gy and 50.6 Gy in 22 fractions simultaneously) and concurrent chemotherapy. The pCR rate was 31.0%. Only four (6.9%) patients experienced postoperative complications.[@b15-cmar-11-1579] In another Chinese study, by Zhu et al, 50 Gy was delivered to the pelvic area, and the primary tumor was boosted to 55 Gy. PCR was observed in 23.7% of patients. The postoperative complication incidence rate was 17.1%.[@b16-cmar-11-1579] A Slovenia study enrolled 51 patients with stages II--III rectal cancer. A dose of 41.8 Gy in 22 fractions was delivered to the pelvic area. T2--T3 tumors were concomitantly boosted to 46.2 Gy and a T4 tumor was boosted to 48.4 Gy. PCR was achieved in 12 (25.5%) patients, and only 2 patients developed ≥ grade 3 acute toxicities.[@b17-cmar-11-1579] In the study by Tey et al, with 55 Gy in 25 fractions to the primary tumor, 35% of patients obtained pCR.[@b18-cmar-11-1579] A meta-analysis including 487 patients also showed a high pCR rate (20.4%) with ≥60 Gy dose-escalated radiotherapy.[@b19-cmar-11-1579] pCR rates in these studies were higher than previous reports of 13.9%--19.2% without dose escalation.[@b4-cmar-11-1579]--[@b8-cmar-11-1579] In the present study, the pCR rate was 22.7%, which was similar to the meta-analysis with doses ≥60 Gy,[@b19-cmar-11-1579] and the pCR rate was much higher than historical reports on nondose escalated radiotherapy in our institute, in which a dose of 50 Gy in 25 fractions was delivered to the pelvic area with conventional radiotherapy or 3D-CRT, and the pCR rate was 10.1%.[@b20-cmar-11-1579]

IMRT was used in most previous reports of dose-escalated neoadjuvant chemoradiotherapy.[@b15-cmar-11-1579]--[@b18-cmar-11-1579],[@b20-cmar-11-1579] It decreased the dose to the bowel, bladder, and femoral head[@b21-cmar-11-1579] and reduced the toxicities[@b22-cmar-11-1579],[@b23-cmar-11-1579] compared with 3D-CRT. In comparison with IMRT and volumetric modulated arc therapy, patients treated with Tomotherapy had lower doses to the bladder and femoral head and better conformity index and homogeneity index.[@b24-cmar-11-1579] Another advantage of Tomotherapy was the use of the MVCT modality, which allows very precise daily patient positioning. Rectal motion is a potential obstacle for dose escalation of the primary tumor. With daily MVCT, the mean shift of mesorectum space was \<3.2 mm.[@b25-cmar-11-1579] The clinical target volume--planning target volume (CTV--PTV) margin was safely reduced, and the mean PTV was decreased from 1,857.4 to 1,462.0 cc (*P*\<0.01). The V15 of the small bowel decreased from 110.9 to 81.4 cc (*P*\<0.01).[@b26-cmar-11-1579] In the present study, we used margins of 5 mm for the primary tumor and 6--8 mm for CTV, which were smaller than most studies with IMRT.[@b16-cmar-11-1579],[@b17-cmar-11-1579] The margins proved to be safe -- the pelvic failure rate was low (5.0%). Previous studies of primary tumor dose escalation with Tomotherapy were limited but showed good survival or LC and favorable toxicities.[@b27-cmar-11-1579]--[@b30-cmar-11-1579]

The dose delivered to the primary tumor in dose-escalated neoadjuvant chemotherapy for rectal cancer was inclusive. The dose fractionation used in previous studies included 46.2 Gy in 22 fractions (EQD2 =46.6 Gy), 48.4 Gy in 22 fractions (EQD2 =49.1 Gy),[@b17-cmar-11-1579] 50.6 Gy in 22 fractions (EQD2 =51.8 Gy),[@b15-cmar-11-1579] 55 Gy in 25 fractions (EQD2 =55.9 Gy),[@b16-cmar-11-1579],[@b18-cmar-11-1579] 55.2 Gy in 23 fractions (EQD2 =57.0 Gy),[@b27-cmar-11-1579],[@b28-cmar-11-1579],[@b30-cmar-11-1579] 50 Gy in 25 fractions (EQD2 =50 Gy),[@b29-cmar-11-1579],[@b31-cmar-11-1579] and EQD2 ≥60 Gy (pooled analysis, with sequential/simultaneous external beam radiotherapy or brachytherapy).[@b19-cmar-11-1579] In most studies without dose escalation, 45--50 Gy was delivered to the pelvic area.[@b4-cmar-11-1579]--[@b8-cmar-11-1579] The dose-escalated study by But-Hadzic et al delivered only 46.2/48.4 Gy to the primary tumor and 41.8 Gy to the pelvic area in 22 fractions.[@b17-cmar-11-1579] This study just reduced the dose delivered to the pelvic area rather than primary dose escalation. In the present study, the dose fractionation was 55 Gy in 25 fractions, with an EQD2 of 55.9 Gy. With this dose fractionation delivered with Tomotherapy, 80.1% of patients received sphincter-preserving surgery. The pCR rate was 22.7%. Only 36 patients (25.5%) experienced treatment failure, and 7 patients (5.0%) developed pelvic failure. The treatment outcome was promising.

In this study, grade 3 or greater acute leukopenia and diarrhea rates were just 5.7% and 7.8%, respectively, and only 10.6% of patients developed postoperative complications. The toxicities were not significantly higher than previous studies without dose escalation[@b4-cmar-11-1579]--[@b8-cmar-11-1579] and were similar to the previous, dose-escalated studies.[@b15-cmar-11-1579]--[@b18-cmar-11-1579],[@b21-cmar-11-1579],[@b27-cmar-11-1579]--[@b30-cmar-11-1579] The toxicity was also lower than our non-dose escalated study with conventional radiotherapy or 3D-CRT, in which 7.9% of patients developed anastomotic fistula, and 6.5% of patients developed bowel obstruction.[@b20-cmar-11-1579]

It is worth noting that one patient developed postoperative anastomotic stenosis. This patient was diagnosed with T3bN1aM0 disease located 5 cm from the anal verge, underwent sphincter-preserving TME, and obtained pCR. However, ileostomy closure could not be performed because of postoperative anastomotic stenosis. Considering the potential association with dose escalation, we constrained the dose to the sigmoid with D2cc ≤45 Gy, and no anastomotic stenosis was observed thereafter.

Considering the comparatively low toxicity of dose-escalated radiotherapy,[@b15-cmar-11-1579]--[@b18-cmar-11-1579],[@b21-cmar-11-1579],[@b27-cmar-11-1579]--[@b30-cmar-11-1579] a higher escalated dose was tried. The RECTAL BOOST study was a randomized control trial to compare 65 Gy (50 Gy in 25 fractions plus 15 Gy in 5 fractions, EQD2 =66.3 Gy) to 50 Gy for locally advanced rectal--cervical cancer patients.[@b32-cmar-11-1579] Recruitment for this study was started in September 2014.

Tumor regression after chemoradiotherapy, especially pCR, was regarded as an important prognostic factor. A retrospective study by the MD Anderson Cancer Center showed that tumor response was associated with 5-year recurrence-free survival, distant-metastasis rate, and local recurrence.[@b4-cmar-11-1579] In our study, pCR was independently prognostic of DFS but could not improve OS and LC. The results may be related to short follow-up time. Long-term follow-up is needed.

Conclusion
==========

This study indicates that neoadjuvant, image-guided Tomotherapy with 55 Gy boosted to the primary tumor was well tolerated and resulted in high rates of sphincter-preserving surgery, pCR, LC, and DFS for locally advanced rectal cancer. Patients' survival will be evaluated with longer follow-up.
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![(**A**) OS, (**B**) DFS, and (**C**) LC rates of rectal cancer patients who received neoadjuvant chemoradiotherapy followed by surgery.\
**Abbreviations:** DFS, disease-free survival; LC, local control; OS, overall survival.](cmar-11-1579Fig1){#f1-cmar-11-1579}

![Patients with pCR (**A**) and sphincter-preservation (**B**) had longer DFS (*P*=0.019, *P*=0.027, respectively).\
**Abbreviations:** DFS, disease-free survival; pCR, pathological complete response.](cmar-11-1579Fig2){#f2-cmar-11-1579}

###### 

Characteristics of patients and tumors

  Characteristics              n                           Percentage (%)
  ---------------------------- --------------------------- ----------------
  Age (years)                  Median 59 (range, 50--67)   
  Gender                                                   
   Male                        99                          70.2
   Female                      42                          29.8
  Tumor differentiation                                    
   Well differentiated         24                          17.0
   Moderately differentiated   84                          59.6
   Poorly differentiated       22                          15.6
   Uncertain type              11                          7.8
  Pretreatment tumor stage                                 
   T2                          12                          8.5
   T3                          113                         80.1
   T4                          16                          11.4
  Pretreatment node status                                 
   N0                          20                          14.2
   N1                          64                          45.4
   N2                          57                          40.4
  Primary tumor location                                   
   Low (\<5 cm)                88                          62.4
   Mid (≥5 cm)                 53                          37.6
  Chemotherapy regiment                                    
   Capecitabine                80                          56.7
   XELOX                       61                          43.3
  Postoperative chemotherapy                               
   Yes                         99                          70.2
   No                          42                          29.8

###### 

Univariate analysis of prognostic factors in OS, DFS, and LC

  Variables                OS      DFS     LC                      
  ------------------------ ------- ------- ------- ------- ------- -------
  Age (years)              0.759   0.384   0.542   0.462   0.003   0.960
   ≤60                                                             
   \>60                                                            
  Gender                   0.068   0.794   0.065   0.799   0.551   0.458
   Male                                                            
   Female                                                          
  Sphincter preservation   0.312   0.577   4.876   0.027   0.617   0.432
   Yes                                                             
   No                                                              
  Downstaging              3.574   0.059   2.044   0.153   1.590   0.207
   Yes                                                             
   No                                                              
  Chemotherapy regiment    0.394   0.530   2.639   0.104   3.108   0.078
   Alone                                                           
   Combination                                                     
  pCR                      0.000   0.100   5.439   0.019   0.000   0.100
   Yes                                                             
   No                                                              
  Adjuvant chemotherapy    0.454   0.500   0.685   0.408   1.073   0.300
   Yes                                                             
   No                                                              

**Abbreviations:** DFS, disease-free survival; LC, local control; OS, overall survival; pCR, pathological complete response.

###### 

Multivariate analysis of the prognosis of DFS

  Variables                X[@b2-cmar-11-1579]   *P*-value   HR (95% CI)
  ------------------------ --------------------- ----------- -------------------
  Sphincter preservation   3.728                 0.054       0.44 (0.19--1.01)
  pCR                      4.108                 0.043       0.13 (0.02--0.93)

**Abbreviation:** DFS, disease-free survival; pCR, pathological complete response.
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